Study M217
Study name | Sonawalla SB 1999 |
Title | Compounds containing cytosolic choline in the basal ganglia: a potential biological marker of true drug response to fluoxetine |
Overall design | The aim of this study was to examine the relationship between true drug response and choline-creatine ratios in the basal ganglia of depressed patients treated with fluoxetine. The authors evaluated drug-free outpatients with major depression before (n = 41) and after (n = 15) 8 weeks of fluoxetine 20 mg/day treatment, by using proton magnetic resonance spectroscopy. Choline-creatine and N-acetylaspartate-creatine ratios at baseline and after 8 weeks of fluoxetine treatment among patients with true drug response (responder group) and patients with placebo pattern response/nonresponse (nonresponder group) were compared. Patients were assessed weekly by using the Clinical Global Impression (CGI) severity and improvement scales. A score of 1 ("very much improved") or 2 ("much improved") on the CGI improvement scale in any week was considered improved. Metabolite quantification was reported relative to total creatine as the reference peak. |
Study Type | Type2; Type4; |
Data available | Unavailable |
Organism | Human; |
Categories of depression | Depressive disorder; Depression; Depression; |
Criteria for depression | DSM-III-R diagnosed MDD, HAMD-17 >= 16 |
Sample size | 15 |
Tissue | Central; Brain; Basal ganglia; |
Platform | MRS; MRS: Signa 1.5 T scanner (General Electric Medical Systems, Milwaukee); |
PMID | |
DOI | |
Citation | Sonawalla SB, Renshaw PF, Moore CM, et al. Compounds containing cytosolic choline in the basal ganglia: a potential biological marker of true drug response to fluoxetine. Am J Psychiatry 1999;156(10):1638-40. |
Metabolite | Choline-containing compounds/(Creatinine and Phosphocreatinine) ratio; |
